Studies have shown that a significant number of eligible breast cancer patients are not offered genetic testing or referral to genetic counseling. To increase access to genetic testing in South Eastern Norway, testing has since 2014 been offered directly to breast cancer patients by surgeons and oncologists. This practice is termed “mainstreamed genetic testing”. The aim of this study was to investigate to what extent patients in South Eastern Norway are offered testing. Three hundred and sixty one patients diagnosed in 2016 and 2017 at one regional and one university hospital in South Eastern Norway were included. Data on whether the patients fulfilled the criteria, whether they had been offered testing and if they were tested were collected. In total, 26.6% (96/361) fulfilled the criteria for testing. Seventy five percent (69/92) of these were offered testing, and 71.7% (66/92) were tested. At the university hospital, 90.2% (37/41) of eligible patients were offered testing, and at the regional hospital 62.7% (32/51). Fifty two percent (12/23) of eligible patient not offered testing were younger than 50 years at time of diagnosis. As many as 95.4% (125/131) of all patients who were offered testing, wanted to be tested. The majority of patients who fulfilled the criteria were offered testing, supporting the practice of mainstreamed genetic testing. There were nevertheless differences in rates of testing between the hospitals that affected all groups of patients, indicating that genetic testing may not be equally accessible to all patients. We suggest that efforts should be made to increase awareness and improve routines for genetic testing of breast cancer patients in Norway.

中文翻译：

---

挪威东南部两家医院对乳腺癌患者进行的主流基因检测。

研究表明，没有为大量合格的乳腺癌患者提供基因检测或遗传咨询服务。为了增加在挪威东南部进行基因检测的机会，自2014年以来，外科医生和肿瘤科医生直接向乳腺癌患者提供了检测。这种做法被称为“主流遗传检测”。这项研究的目的是调查在挪威东南部的患者接受检测的程度。纳入2016年和2017年在挪威东南部的一家地区医院和一所大学医院诊断的361位患者。收集有关患者是否符合标准，是否接受检查以及是否接受检查的数据。总计有26.6％（96/361）符合测试标准。其中百分之七十五（69/92）提供了测试，而百分之71.7％（66/92）得到了测试。在大学医院中，有90.2％（37/41）的合格患者接受了检测，在地区医院中有62.7％（32/51）。未接受测试的合格患者中有52％（12/23）在诊断时年龄小于50岁。提供测试的所有患者中，多达95.4％（125/131）想要接受测试。为符合标准的大多数患者提供了检测，支持了主流基因检测的实践。但是，影响所有患者组的医院之间的检测率存在差异，这表明基因检测可能并非对所有患者均适用。